Business Segments GSK plc

Equities

Market Closed - London S.E. Other stock markets 09:05:26 08/05/2026 pm IST			5-day change	1st Jan Change
1,843.00 ^GBX	-0.83%		-3.05%	+1.01%

07/05	Halozyme, GSK Enter Collaboration, Licensing Agreement	MT
07/05	Halozyme announces global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple promising oncology targets	RE

Breakdown by Business Segment (GBP)

Fiscal Period: December	2021	2022	2023	2024	2025
Biological Products
Commercial Operations	-	2.93TCr	3.03TCr	3.14TCr	3.27TCr
D&A	-	83Cr	89Cr	91Cr	87Cr
Operating Income	-	1.36TCr	1.47TCr	1.53TCr	1.63TCr
Corporate and Other Unallocated Turnover	-	-	-	-	-
Operating Income	-37Cr	-38Cr	-26Cr	-34Cr	-23Cr
D&A	5.4Cr	11Cr	11Cr	7.4Cr	7.9Cr
D&A	80Cr	74Cr	72Cr	100.2Cr	81Cr
Dental Care Products
Consumer Healthcare	960.7Cr	-	-	-	-
D&A	23Cr	-	-	-	-
Operating Income	223.9Cr	-	-	-	-
Pharmaceutical Research and Development
Operating Income	-348.9Cr	-506Cr	-560.7Cr	-584.5Cr	-625.1Cr
D&A	32Cr	47Cr	57Cr	57Cr	55Cr
Pharmaceutical Products
Vaccines	677.8Cr	-	-	-	-
D&A	42Cr	-	-	-	-
Operating Income	225.6Cr	-	-	-	-
Pharmaceuticals	1.77TCr	-	-	-	-
D&A	55Cr	-	-	-	-
Operating Income	817Cr	-	-	-	-

Geographical breakdown of sales (GBP)

Fiscal Period: December	2021	2022	2023	2024	2025
United States (US)	1.51TCr	1.45TCr	1.58TCr	1.64TCr	1.69TCr
Total Assets	1.79TCr	1.4TCr	1.33TCr	1.4TCr	1.45TCr
Operating Income	-	-	-	-	-
Rest of World	1.8TCr	1.41TCr	1.38TCr	1.43TCr	827.5Cr
Total Assets	1.54TCr	655.9Cr	660.6Cr	558.8Cr	553.2Cr
Operating Income	-	-	-	-	-
Europe	-	-	-	-	685Cr
United Kingdom (UK)	98Cr	70Cr	69Cr	71Cr	68Cr
Total Assets	661.8Cr	513.4Cr	646.4Cr	780.3Cr	846.6Cr
Operating Income	-	-	-	-	-
Total Assets	506.5Cr	541.5Cr	533.7Cr	537.8Cr	545.3Cr
Total Assets	655.2Cr	3.4Cr	-	-	-
Inter-Segment Turnover	-	-	-	-	-